PBL 8 - Parkinson's and Basal Ganglia Flashcards

1
Q

Draw a flow chart to show the connections between the basal ganglia. Include the direct pathway and indirect pathway.

A

See “Motor Control” poster.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Draw and label the basal ganglia in a coronal section.

A

See “Basal Ganglia” poster.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Draw and label the basal ganglia in a transverse section.

A

See “Basal Ganglia” poster.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How big is the thalamus?

A

Length: 3cm
Height: 2cm
Width: 2.5cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the blood supply of the thalamus?

A

Branches of the posterior cerebral artery

  1. Posterior communicating artery
  2. Paramedian thalamic-subthalamic arteries
  3. Inferolateral arteries
  4. Posterior medial/lateral choroidal arteries

Anatomical variant - artery of Percheron
Single artery branching from the posterior cerebral artery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the 2 parts of the substantia nigra?

A

Pars compacta

Pars reticulata

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the direct pathway of the motor loop.

A
  1. Cerebral cortex activates the putamen
  2. The putamen sends inhibitory signals to the globus pallidus (internal) and substantia nigra (reticulata) – neurotransmitter: GABA
    a. Normally, the GPi and SNr would inhibit the thalamus – neurotransmitter: GABA
  3. Therefore, when inhibited by the putamen, this allows the thalamus to be activated
  4. The thalamus sends excitatory signals to the cerebral cortex
  5. The cerebral cortex then sends excitatory signals via the descending motor pathways to control motor neurons
    a. This causes movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the indirect pathway of the motor loop.

A
  1. Cerebral cortex activates the putamen
  2. The putamen sends inhibitory signals to the globus pallidus (external) – neurotransmitter: GABA
    a. Normally, the GPe would inhibit the GPi and SNr, thus allowing the thalamus to be activated, consequently allowing cerebral activation of motor neurons (and therefore movement)
  3. Therefore, when inhibited by the putamen, the GP (external) allows the GP (internal) and SN (reticulata) to be activated
    a. This causes inhibition of the thalamus
    b. This means that the thalamus does not stimulate the cerebral cortex
    c. This means that there is no stimulation of motor neurons
    d. Therefore, there is no movement
  4. Role of subthalamic nuclei in the indirect pathway:
    a. Activation of the globus pallidus (external) inhibits the subthalamic nucleus
    b. Normally, the subthalamic nucleus would send excitatory signals to the GP (internal) and SN (reticulata), thus inhibiting the thalamus
    c. Therefore, when inhibited by the GP (external), the subthalamic nucleus stops the GP (internal) and SN (reticulata)
    - –This allows activation of the thalamus, therefore causing movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the role of the substantia nigra in the direct and indirect pathways.

A

Substantia nigra produces dopamine

Effect on the direct pathway:

  1. Dopamine produced by the SN (compacta) acts on the D1 and D5 receptors of the putamen
  2. This causes excitation of the direct pathway, therefore inhibiting the GP (internal) and SN (reticulata)
  3. Therefore, the thalamus is activated and causes movement

Effect on the indirect pathway:

  1. Dopamine produced by the SN (compacta) acts on the D2-D4 receptors of the putamen
  2. This causes inhibition of the indirect pathway, therefore activating the GP (external)
  3. This allows inhibition of the GP (internal) and SN (reticulata)
  4. This allows activation of the thalamus and causes movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does the spinal cord control movement?

A

Central pattern generators (CPGs)

Function: produce rhythmic motor outputs (movements) without sensory feedback or descending commands from the brain

Example: walking

  1. CPG creates alternating activity in flexor/extensor muscles via two sets of pattern generating neurons into the legs
  2. Reciprocal inhibitory connections between these sets of pattern generating neurons co-ordinate their activity, so that there is alternating activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List the different processes involved in controlling movement.

A
  1. Control of movement in the cerebral cortex
    a. Primary motor cortex
    b. Premotor area
    c. Supplementary motor area
    d. Somatosensory area
  2. Initiation of movement via the motor loop in the basal ganglia
  3. Segmental connections to motor neurons in the spinal cord
    a. Reflexes
  4. Intrinsic spinal cord control of movement
    a. Central pattern generators
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the process of catecholamine synthesis.

A
  1. Phenylalanine (an essential amino acid) is converted to tyrosine via phenylalanine hydroxylase (mostly in the liver)
    a. Cofactors needed for reaction:
    - –Tetrahydrobiopterin
    - –Molecular oxygen (O2)
  2. Tyrosine is converted to DOPA (or L-DOPA) via tyrosine hydroxylase
    a. Cofactors needed for reaction:
    - –Tetrahydrobiopterin
    - –Iron (Fe2+)
  3. DOPA is converted to dopamine via aromatic amino acid decarboxylase
    a. Cofactors needed for reaction:
    - –Pyridoxal phosphate
    b. By products: CO2
  4. Dopamine is transported into synaptic vesicles via the vesicular monoamine transporter (VMAT)
  5. In the vesicles, dopamine is converted to noradrenaline via dopamine-β-hydroxylase
    a. Cofactors needed for reaction:
    - –O2
    - –L-ascorbic acid
  6. Noradrenaline is converted to adrenaline via phenylethanolamine N-methyltransferase
    a. Cofactors needed for reaction:
    - –S-adenyosyl-L-methionine
  7. Influx of Ca2+ into the neuron will then cause emptying of these vesicles into the synaptic cleft, causing AP transmission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the rate limiting enzyme in dopamine synthesis?

A

Tyrosine hydroxylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is tyrosine hydroxylase activity regulated?

A
  1. Phosphorylation by kinases
  2. Dephosphorylation
  3. Negative feedback by dopamine
  4. Oxidation by nitrates
  5. Formation of protein complexes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the inactivation mechanism for dopamine.

A
  1. Reuptake via dopamine transporters
  2. Enzymatic breakdown
    a. Monoamine oxidase (MAO-A and MAO-B)
    b. Catechol-O-methyl transferase (COMT)
    c. Aldehyde dehydrogenase
  3. Diffusion into the circulation
    a. Destroyed in liver by MAO and COMT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

List the dopaminergic pathways in the CNS.

What is the function of each?

A
  1. Nigrostriatal pathway
    a. Motor planning
  2. Mesolimbic pathway
    a. Motivation
    b. Emotions
    c. Reward
  3. Mesocortical pathway
    a. Cognition
    b. Executive functions
    c. Emotions
  4. Tuberohypophyseal system
    a. Tonic inhibition of prolactin release
17
Q

What are the other monoamines in the brain?

A
  1. Noradrenaline

2. Serotonin

18
Q

Define Parkinson’s disease.

A

A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement; associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine

19
Q

What are the causes of Parkinson’s?

A
  1. Genetics
  2. Unknown
  3. Environmental toxins
20
Q

Describe the pathophysiology of Parkinson’s disease.

A
  1. Neurodegenerative disease
  2. There are 3 main processes leading to loss of dopaminergic fibres:
    a. Oxidative stress
    b. Apoptosis
    c. Mitochondrial disorders
  3. Loss of dopaminergic neurons in the substantia nigra:
    a. Poisoning of cells
    - –Auto-oxidation of dopamine releases quinones and free radicals
    - –These can poison cells
  4. Hyaline found in substantia nigra cells
  5. Atrophy of substantia nigra
  6. Depletion of neurons in locus ceruleus
  7. Reduced dopamine output from the substantia nigra to the globus pallidus leads to reduced inhibitory effects on the subthalamic nucleus
    a. This causes activation of the subthalamic nucleus
    b. This causes inhibition of the cerebral cortex and therefore NO movement (bradykinesia)
21
Q

List the main clinical features of Parkinson’s and give some examples of each.

A
  1. Initial non-specific symptoms
    a. Tiredness
    b. Aching limbs
    c. Mental slowness
    d. Depression
    e. Small handwriting
  2. Cognitive impairment
    a. Only in 1/3 of cases
  3. General physical symptoms
    a. Expressionless face
    b. Soft, rapid, indistinct speech
    c. Flexed posture
    d. Impaired postural reflexes
  4. Gait disturbances
    a. Slow to start walking
    b. Shortened stride
    c. Rapid, small stride length; tendency to shorten strides (festination)
    d. Reduced arm swing
    e. Impaired balance on turning
  5. Tremors
    a. Resting tremor
    b. Postural tremor (present on action or posture)
  6. Rigidity
    a. Cogwheel
    b. Plastic (lead pipe) rigidity
  7. Bradykinesia
    a. Slowness in initiating/repeating movements
    b. Impaired fine movements
  8. Autonomic symptoms
    a. Lacrimation
    b. Dysphagia
    c. Orthostatic hypotension
    d. Thermal regulation
    e. Constipation
    f. Impotence
    g. Urinary incontinence
  9. Other features:
    a. Normal muscle strength
    b. Normal reflexes
22
Q

Describe the non-pharmacological management of Parkinson’s.

A
  1. Group support
  2. Exercises
  3. Education
  4. Adequate nutrition
  5. Botulinium injection (for dystonias)
23
Q

List the types of antiparkinson drugs.

A
  1. Increasing dopamine levels
    a. Levodopa
    b. Pramipexole
    c. Ropinirole
  2. Dopamine receptor antagonists
  3. Prevent breakdown of dopamine (MAO-B inhibitors)
    a. Selegiline
    b. Rasagiline
  4. Anticholinergic drugs
    a. Trihexyphenidyl
    b. Benztropine
24
Q

Describe the pharmacological treatment of Parkinson’s.

A
  1. MOA-B inhibitors
    a. Rasagiline
    b. Selegiline
  2. Dopamine agonists
    a. Pramipexole
    b. Ropinirole
  3. Adjuvant therapy for when first line therapy becomes ineffective
    a. Apomorphine
  4. Anticholinergic drugs
  5. Levodopa
  6. COMT inhibitors
    a. Entacapone
    b. Tolcapone
25
Q

What is the mechanism of action of levodopa?

A
  1. Metabolic precursor of dopamine (L-DOPA)
    a. This can cross the blood brain barrier
    b. In the brain, levodopa is then converted to dopamine
  2. Enhances dopamine synthesis in surviving neurons in the substantia nigra
    a. Becomes less effective as time goes on
    b. Causes motor fluctuations
  3. Administered with carbidopa (DOPA decarboxylase inhibitor)
    a. Inhibits peripheral metabolism of levodopa
    b. Doesn’t cross blood brain barrier, therefore only acts in the periphery